BioTheranostics Raises $32M in Private Equity Financing; Will Spin Off From BioMérieux | GenomeWeb

NEW YORK (GenomeWeb) – BioTheranostics announced today that it has raised $32 million in a private equity financing round, and will be spun off from parent company BioMérieux as a result.

The financing round was led by MVM Life Science Partners, with participation from Canepa Advanced Healthcare Fund and HealthQuest Capital. BioMérieux will remain a minority shareholder in the newly independent company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.